Drug Detail
VIR-7831 is a SARS-CoV-2 neutralizing monoclonal antibody.
Study Purpose
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
